Because GlcNAc treatment enhances the galectin-3-glycan-binding via increasing N-glycan branching and improve (re)myelination by forming lattice on PGDFRα as mentioned above, it also would be a potential therapeutic strategy for genetic disorders such as metachromatic leukodystrophy with increased sulfation in glycosaminoglycans and glycolipids. This evidence concerns the gene LGALS3 and hereditary disease.